Benralizumab + Placebo
Phase 3Active 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Hypereosinophilic Syndrome
Conditions
Hypereosinophilic Syndrome
Trial Timeline
Jul 20, 2020 → Dec 30, 2026
NCT ID
NCT04191304About Benralizumab + Placebo
Benralizumab + Placebo is a phase 3 stage product being developed by AstraZeneca for Hypereosinophilic Syndrome. The current trial status is active. This product is registered under clinical trial identifier NCT04191304. Target conditions include Hypereosinophilic Syndrome.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (14)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05692180 | Phase 3 | Recruiting |
| NCT05251909 | Phase 3 | Terminated |
| NCT04612790 | Phase 3 | Terminated |
| NCT04191304 | Phase 3 | Active |
| NCT04185012 | Phase 3 | Completed |
| NCT03953300 | Approved | Active |
| NCT04053634 | Phase 3 | Completed |
| NCT03470311 | Phase 3 | Completed |
| NCT03473977 | Phase 2/3 | Completed |
| NCT03186209 | Phase 3 | Completed |
| NCT02322775 | Phase 3 | Completed |
| NCT01947946 | Phase 3 | Terminated |
| NCT01928771 | Phase 3 | Completed |
| NCT01914757 | Phase 3 | Completed |
Competing Products
4 competing products in Hypereosinophilic Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| STI571 | Novartis | Phase 2 | 52 |
| Nilotinib | Novartis | Pre-clinical | 23 |
| imatinib mesylate | Novartis | Phase 2 | 52 |
| imatinib mesylate | Novartis | Phase 2 | 52 |